慢性乙型肝炎患者核苷(酸)类似物抗病毒治疗依从性的影响因素分析

吴小凤; 李玉芳; 张驰; 张利利; 马英

doi:10.3969/j.issn.1001-5256.2019.10.013

慢性乙型肝炎患者核苷(酸)类似物抗病毒治疗依从性的影响因素分析

DOI: 10.3969/j.issn.1001-5256.2019.10.013

1. 临沂金锣医院消化内科
2. 宁夏医科大学总医院感染疾病科
3. 北京大学人民医院呼吸内科
4. 新乡医学院第一附属医院感染疾病科
5. 宁夏医科大学

详细信息

中图分类号: R512.62
计量
- 文章访问数: 421
- HTML全文浏览量: 57
- PDF下载量: 145
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-02
- 出版日期: 2019-10-20

Influencing factors for compliance with antiviral therapy with nucleos(t) ide analogues in patients with chronic hepatitis B

Department of Gastroenterology,Linyi Jinluo Hospital

摘要

摘要: 目的分析宁夏医科大学总院慢性乙型肝炎（CHB）患者核苷（酸）类似物（NAs）抗病毒治疗依从性现况。方法选择2017年5月-2017年12月就诊宁夏医科大学总医院感染科（包括门诊、住院部）,接受NAs抗病毒治疗的CHB患者。通过对人口学资料、乙型肝炎家族史、医生告知详细否、生活作息、体育锻炼、依从性、乙型肝炎知识知晓情况、健康信念、社会支持等方面内容的问卷调查,分析不同因素对CHB患者NAs治疗依从性的影响。计量资料非正态分布组间比较采用Wilcoxon秩和检验。计数资料组间比较采用χ2检验或Fisher确切概率法。采用多因素logistic回归分析影响CHB患者NAs抗病毒治疗依从性的因素。结果612份调查问卷,回收600份,回收率为98%,有效率为100%。600例CHB患者中NAs抗病毒治疗依从好的有334人（55. 67%）,而依从性差的266人（44. 33%）。依从性差的CHB患者中,不遵从医生建议,自行选择其他药物的有56人（21. 05%）;有时忘记服药的206人（77. 44%）;有时不注意服药（时间、剂量、频次） 187人（70. 30%）;症状改善自行减药、停药的1...
- 乙型肝炎,慢性 /
- 抗病毒药 /
- 服药依从性 /
- 影响因素分析
Abstract: Objective To investigate the current status of compliance with antiviral therapy with nucleos(t) ide analogues(NAs) among chronic hepatitis B(CHB) patients treated in General Hospital of Ningxia Medical University. Methods The CHB patients who received antiviral therapy with NAs at the outpatient and inpatient services of Department of Infectious Diseases,General Hospital of Ningxia Medical University,from May to December,2017 were enrolled. A questionnaire survey was performed for demographics,family history of CHB,detailed doctor's advice,daily routines,physical exercise,compliance,awareness of the knowledge about hepatitis B,health belief,and social support,and the influence of various factors on compliance with NAs treatment was analyzed. The Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between groups,and the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. A multivariate logistic regression analysis was used to investigate the influencing factors for compliance with antiviral therapy with NAs among CHB patients. Results A total of 612 questionnaires were distributed,among which 600 were collected,with a questionnaire recovery rate of 98% and a valid rate of 100%. Among the 600 CHB patients,334(55. 67%) had good compliance with the antiviral therapy with NAs and 266(44. 33%) had poor compliance. Among the 266 CHB patients with poor compliance,56(21. 05%) did not follow the doctor's advice and took other drugs,206(77. 44%) sometimes forgot medication,187(70. 30%) sometimes did not pay attention to medication(time,dose,and frequency),135(50. 75%) reduced or stopped drugs after symptoms were improved,and 100(37. 59%) stopped the drugs due to symptom aggravation or appearance of other symptoms. The univariate analysis showed that 13 indices were the influencing factors for compliance with NAs treatment among CHB patients(all P < 0. 05). Amultivariate analysis was performed for these 13 indices and the results showed that race(odds ratio [OR]= 0. 218,95% confidence interval [CI]: 0. 076-0. 996,P = 0. 007),mode of medical payment(OR = 0. 772,95% CI: 0. 445-0. 919,P < 0. 001),physical exercise(OR = 2. 55,95% CI: 1. 472-6. 545,P = 0. 020),level of social support(OR = 0. 836,95% CI: 0. 649-0. 947,P < 0. 001),awareness of the outcome of incompliance(OR = 0. 577,95% CI: 0. 393-0. 886,P < 0. 001),and self-efficacy(OR = 0. 094,95% CI:0. 074-0. 328,P < 0. 001) were independent influencing factors for compliance with NAs treatment among CHB patients. Conclusion Compliance with antiviral therapy among CHB patients is closely associated with the mode of medical payment,psychological state,and self-management ability. Related measures,such as improvement of patients' ability to pay medical expenses,education on disease risk for patients,and reduction of social discrimination,can help to improve treatment compliance.
- hepatitis B,chronic /
- antiviral agents /
- medication adherence /
- root cause analysis

HTML全文

参考文献(28)

[1] World Health Organization. Hepatitis B[EB/OL].(2014-07)[2015-04-02]. http://www. who. int/mediacentre/factsheets/fs204/en/.

[2] FAN R,SUN J,HOU JL,et al. Antiviral therapy for chronic hepatitis B:Current status and perspectives[J]. J Clin Heptal,2016,32(11):2029-2032.(in Chinese)樊蓉,孙剑,侯金林,等.慢性乙型肝炎抗病毒治疗现状及展望[J].临床肝胆病杂志,2016,32(11):2029-2032.

[3] CHOTIYAPUTTA W,HONGTHANAKORN C,OBERHELMAN K,et al. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs[J]. J Viral Hepat,2012,19(3):205-212.

[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[5] WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[J/OL]. Geneva:World Health Organization,2015.

[6] LOCARNINI S,HATZAKIS A,CHEN DS,et al. Strategies to control hepatitis B:Public policy,epidemiology,vaccine and drugs[J]. J Hepatol,2015,62(1 Suppl):s76-s86.

[7] HONGTHANAKORN C,CHOTIYAPUTTA W,OBERHELMAN K,et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice[J]. Hepatology,2011,53(6):1854-1863.

[8] HA NB,HA NB,GARCIA RT,et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B[J]. Dig Dis Sci,2011,56(8):2423-2431.

[9] KAMEZAKI H,KANDA T,WU S,et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus:Vvirological breakthrough is also dependent on adherence to medication[J].Scand J Gastroenterol,2011,46(9):1111-1117.

[10] PENG J,YIN J,CAI SH,et al. Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients:results from a 1-year follow-up study[J]. Patient Prefer Adherence,2015,9:41-45.

[11] LIEVELD FI,van VLERKEN LG,SIERSEMA PD,et al. Patient adherence to antiviral treatment for chronic hepatitis B and C:a systematic review[J]. Ann Hepatol,2013,12(3):380-391.

[12] HAMILTON GA. Measuring adherence in a hypertension clinical trial[J]. Eur J Cardiovasc Nurs,2003,2(3):219-228.

[13] XU WH,WANG Q,LIANG WX. Reliability and validity of Morisky Questionnaire in measurement of the compliance with hypertensive medications[J]. Chin J Prev Contr Chron Non-commun Dis,2007,15(5):424-426.(in Chinese)许卫华,王奇,梁伟雄. Morisky问卷测量高血压患者服药依从性的信度和效度评价[J].中国慢性病预防与控制,2007,15(5):424-426.

[14] LAI SL. Methods for clinical research based on integrated traditional Chinese and Western medicine[M]. Beijing:Science Press,2003:100.(in Chinese)赖世隆.中西医结合临床科研方法[M].北京:科学出版社,2003:100.

[15] OSTERBERG L,BLASCHKE T. Adherence to medication[J].N Engl J Med,2005,353(5):487-497.

[16] ZHANG JM. Analysis of compliance with nucleoglycan therapy in patients with chronic hepatitis B[J]. J Aerospace Med,2015,26(4):431-432.(in Chinese)张建明.慢性乙肝患者对核甘类药物治疗的依从性分析[J].航空航天医学杂志,2015,26(4):431-432.

[17] LI GJ,ZOU HH,XIU ZL,et al. Multiple regression analysis of factors related to compliance with antiviral therapy in patients with hepatitis B[J]. China Mod Doct,2010,48(28):32-33.(in Chinese)李国军,邹何慧,修自力,等.乙型肝炎抗病毒治疗依从性相关因素多元回归分析[J].中国现代医生,2010,48(28):32-33.

[18] ZHU CH,WU YK,LI XY,et al. Compliance status and influencing factors of patients with chronic HBV infection in longterm follow-up cohort[J]. Guangdong Med,2016,37(23):3578-3582.(in Chinese)朱昌浩,吴元凯,李向永,等.慢性HBV感染者长期随访队列患者依从性现状及其影响因素[J].广东医学,2016,37(23):3578-3582.

[19] ZHAO Y,ZHANG BP,ZHANG GS,et al. Influencing factors for medication compliance with nucleoside drugs in patients with chronic hepatitis B:A logistic regression analysis[J].Chin J Integr Tradit West Med Liver Dis,2013,23(5):309-311.(in Chinese)赵艳,张伯鹏,张国顺.慢性乙型肝炎核苷类药物治疗依从性影响因素Logistic回归分析[J].中西医结合肝病杂志,2013,23(5):309-311.

[20] CHEN JE. Causes influencing compliance with antiviral therapy in patients with hepatitis B and related nursing strategies[J]. Chin J Clin Ration Drug Use,2011,4(29):88-89.(in Chinese)陈菊娥.影响乙肝患者抗病毒治疗依从性的原因分析及护理对策研究[J].临床合理用药杂志,2011,4(29):88-89.

[21] POLIS S,ZABLOTSKA-MANOS I,ZEKRY A,et al. Adherence to hepatitis B antiviral therapy:A qualitative study[J].Gastroenterol Nurs,2017,40(3):239-246.

[22] XU MM,CHEN Y. Current research on adherence to antiviral therapy in patients with chronic hepatitis B[J]. J Clin Heptal,2015,31(10):1735-1739.(in Chinese)徐曼曼,陈煜.慢性乙型肝炎患者抗病毒治疗依从性的研究现状[J].临床肝胆病杂志,2015,31(10):1735-1739.

[23] LUO KX. Hepatitis B basic biology and clinical science[M].2nd Version. Beijing:People’s medical publishing house,2001:226-227.(in Chinese)骆抗先.乙型肝炎基础和临床[M]. 2版.北京:人民卫生出版社,2001:226-227.

[24] SHA L,XU Q,HUA L,et al. Analysis of the relationship between treatment compliance,self-efficacy and social support in patients with chronic hepatitis B[J]. Chin J Modern Nurs,2014,20(32):4075-4078.(in Chinese)沙莉,许勤,华琳,等.慢性乙型肝炎患者治疗依从性与自我效能和社会支持的相关性分析[J].中华现代护理杂志,2014,20(32):4075-4078.

[25] GUO QF,TIAN YW,SUI J. Effect of We Chat on compliance of oral antiviral therapy in patients with hepatitis B[J]. Contemporary Nurs(mid-issue),2017,4:128-129.(in Chinese)郭琴芳,谭友文,眭静.微信在乙肝患者口服抗病毒药治疗依从性中的效果[J].当代护士(中旬刊),2017,4:128-129.

[26] XU LH. Effects of self-efficacy on compliance,self-management and cognition of antiviral therapy in patients with chronic hepatitis B[J]. Chin Foreign Medi Res,2018,16(1):169-170.(in Chinese)许丽红.自我效能对慢性乙肝患者抗病毒治疗依从性、自我管理能力及认知程度的影响分析[J].中外医学研究,2018,16(1):169-170.

[27] ZHAO M. Investigation and analysis of hepatitis B knowledge and treatment compliance in patients with chronic hepatitis B[J]. J Clin Nursing’s Pract,2018,3(27):164.(in Chinese)赵梅.慢性乙型肝炎患者对乙肝知识认知情况及治疗依从性的调查分析[J].实用临床护理学杂志,2018,3(27):164.

[28] CHOTIYAPUTTA W,PETERSON C,DITAH FA,et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B[J]. J Hepatol,2011,54(1):12-18.

施引文献

资源附件(0)

访问统计